ebselen has been researched along with Hearing Loss in 3 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This mouse model of tobramycin-induced ototoxicity is clinically relevant in that it results in an incidence and severity of hearing loss recently documented in clinic." | 8.02 | Ebselen attenuates tobramycin-induced ototoxicity in mice. ( Gu, R; Homan, J; Kil, J; Longenecker, RJ, 2021) |
| "This mouse model of tobramycin-induced ototoxicity is clinically relevant in that it results in an incidence and severity of hearing loss recently documented in clinic." | 4.02 | Ebselen attenuates tobramycin-induced ototoxicity in mice. ( Gu, R; Homan, J; Kil, J; Longenecker, RJ, 2021) |
| "Cisplatin ototoxicity has been associated with the generation of toxic levels of reactive oxygen species (ROS) which can lead to injury or loss of outer hair cells in the organ of Corti, damage to the stria vascularis, and loss of spiral ganglion cells, resulting in permanent hearing loss." | 1.33 | Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. ( Gu, R; Kil, J; Lynch, ED; Pierce, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, R | 2 |
| Longenecker, RJ | 1 |
| Homan, J | 1 |
| Kil, J | 2 |
| Lynch, ED | 1 |
| Pierce, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity[NCT02819856] | Phase 2 | 80 participants (Anticipated) | Interventional | 2017-07-21 | Enrolling by invitation | ||
| Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift[NCT01444846] | Phase 2 | 83 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss[NCT01451853] | Phase 2 | 80 participants (Anticipated) | Interventional | 2018-01-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for ebselen and Hearing Loss
| Article | Year |
|---|---|
Ebselen attenuates tobramycin-induced ototoxicity in mice.
Topics: Animals; Evoked Potentials, Auditory, Brain Stem; Hair Cells, Auditory, Outer; Hearing Loss; Isoindo | 2021 |
Ebselen could be used as anti-inflammatory Nox inhibitor.
Topics: Anti-Inflammatory Agents; Azoles; Catalytic Domain; Hearing Loss; Humans; Isoindoles; NADPH Oxidases | 2012 |
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry, | 2005 |
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry, | 2005 |
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry, | 2005 |
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry, | 2005 |